Recovering Hearts. Saving Lives.
|
|
- Justin Silvester Porter
- 5 years ago
- Views:
Transcription
1 Recovering Hearts. Saving Lives ṬM The Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial November 218 Recovering Hearts. Saving Lives.
2 LEGAL DISCLAIMERS This presentation includes select slides presented by Navin Kapur, MD, executive director of the CardioVascular Center for Research and Innovation at Tufts Medical Center, at the American Heart Association Scientific Sessions 218 in Chicago. The complete slide presentation, Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial, is available in the Abiomed investor website at Impella heart pumps are not FDA approved for use in STEMI patients without cardiogenic shock. This presentation contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities, the Company s guidance for future financial performance and expected regulatory approvals. Each forward-looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statement, including uncertainties associated with development, testing and related regulatory approvals; the potential for future losses; the impact of complex manufacturing processes and high quality requirements; dependence on limited sources of supply; competition; technological change; government regulation; third-party reimbursement to the Company s customers; litigation matters; future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 1-K and Quarterly Report on Form 1-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this presentation or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or otherwise, unless otherwise required by law. U.S. Food and Drug Administration Approvals The Impella 2.5 and Impella CP are indicated for providing temporary (< 6 hours) ventricular support during elective or urgent high risk percutaneous coronary interventions (PCI) performed in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high risk PCI is the appropriate therapeutic option. Use of the Impella 2.5 and the Impella CP in these patients may prevent hemodynamic instability which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events. The Impella 2.5, Impella CP, Impella 5., and Impella LD Catheters, in conjunction with the Automated Impella Controller, are temporary ventricular support devices intended for short term use ( 4 days for the Impella 2.5 and Impella CP, and 6 days for the Impella 5. and Impella LD) and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (<48 hours) following acute myocardial infarction or open heart surgery, or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures.* The intent of the Impella Support Systems therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function. The Impella RP is indicated for providing circulatory assistance for up to 14 days with a body surface area 1.5 m2 who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery. For safety information associated with Abiomed s technologies, visit and The ABIOMED logo, ABIOMED, Impella 2.5, Impella CP, Impella RP, Impella 5., Impella LD and Symphony are registered trademarks of Abiomed, Inc. in the U.S.A. and certain foreign countries. Impella ECP, Impella 5.5, Impella BTR, cvad Registry and Recovering hearts. Saving lives. is a trademark of Abiomed, Inc. Recovering Hearts. Saving Lives.
3 Loaded heart during AMI Unloaded heart during AMI 3 CO CO MAP LA Stretch MAP LA Stretch pvad Support LVEDP LVEDV Wall Stress MVO2 AAR LVEDP LVEDV Wall Stress MVO2 AAR Cardioprotective Effects of Unloading Decreased myocardial oxygen consumption Reduced acute infarct size and subsequent scar size Activation of cardioprotective signaling (i.e., SDF1a/CXCR4 and RISK pathway) Hemodynamic stabilization through reperfusion-dependent arrhythmia Increased cardiac microvascular perfusion into infarct zone Bridge through reperfusion-induced myocardial stunning
4 Preclinical Development of the DTU Concept TandemHeart Delayed Reperfusion (Circulation 213) Impella CP Delayed Reperfusion (JACC HF 215) Impella CP Cardioprotective Biology (JACC 218) Impella CP Preclinical Pilot (JACC 218) Impella CP DTU-STEMI Pilot Trial (Circulation 218) Trans-valvular LV Unloading Limits Myocardial Ischemia and Promotes a Cardioprotective Shift in Myocardial Biology Esposito, Zhang, Qiao and Kapur et al JACC 218 4
5 Infarct Size / Area at Risk (%) The Rationale for the DTU Pilot Before the Pivotal DTU Pivotal DTU? Pilot 2 Reperfusion Alone Esposito, Zhang, Qiao and Kapur et al JACC min 3 min Unloading + Delayed Reperfusion Unloading After Reperfusion 5
6 Door To Unload: STEMI Pilot Trial: Central Hypothesis Compared to LV unloading and immediate reperfusion, LV unloading followed by a 3 minute delay to reperfusion is feasible and safe as defined by: o Successful enrollment and protocol completion (Feasibility) o No increase in major adverse cardiovascular or cerebral events (MACCE Safety) o No increase in infarct size between groups (Safety) 6
7 Results: Procedural Characteristics Clinical Variable U-IR (n=25) U-DR (n=25)* p-value LAD Culprit, n (%) 25 (1) 24 (1) NS Proximal LAD Lesion Location, n (%) 17 (68) 19 (76) NS Mid LAD Lesion Location, n (%) 8 (32) 5 (21) NS Successful Impella CP Implant, n (%) 25 (1) 25 (1) NS Pre-PCI TIMI Flow (After Impella CP Activation) NS Pre-Intervention TIMI Flow -1, n (%) 16 (64) 1 (4) NS Pre-Intervention TIMI Flow 2-3, n (%) 9 (36) 15 (6) NS Post-Intervention TIMI Flow NS Post-Intervention TIMI Flow 3, n (%) 25 (1) 24 (1) NS * 1 patient had no coronary obstruction LAD = Left anterior descending artery TIMI = Thrombolysis In Myocardial Infaction 7
8 Unload to Balloon Time (Minutes) Results: Successful enrollment & protocol completion Zero Bailout PCI in the U-DR Group Enrolled Patients U-DR U-IR 3 minutes of LV Unloading 8
9 DTU-STEMI Results: 3-5 Day CMR Parameters Infarct Size vs Total LV Mass (%) Myocardial Salvage Index (%) Microvascular Obstruction (%) U-IR U-DR CRISP AMI U-IR U-DR CRISP AMI U-IR U-DR CRISP AMI Unloading and delaying reperfusion for 3 minutes did not increase infarct size 9
10 DTU-STEMI Results: Exploratory Subgroup Analysis Infarct Size / Total LV Mass (%) Infarct Size / Area at Risk (%) * Total STE>4 STE>5 STE>6 Total STE>4 STE>5 STE>6 U-DR U-IR 1
11 What did we learn from this Pilot Study? The Door-To-Unload in STEMI Pilot Trial demonstrates for the first time that LV unloading using the Impella CP device with a 3-minute delay before reperfusion is safe and feasible within a relatively short DTB Time. No prohibitive safety signals that would preclude proceeding to a larger pivotal study of LV unloading and delaying reperfusion for 3 minutes were identified. Compared to LV unloading and immediate reperfusion, LV unloading and delaying reperfusion for 3 minutes does not increase infarct size. Among patients with sum STE>6mm, infarct size normalized to the area at risk was significantly lower with 3 minutes of LV unloading before reperfusion compared to LV unloading and immediate reperfusion. 11
12 TERMS AND ACRONYMS: STEMI-DTU PRESENTATION 12 STEMI ST segment Elevation Myocardial Infarction an EKG pattern that identifies acute coronary occlusion, sometimes referred to as a tombstone pattern U-IR Unloading with immediate reperfusion - Impella placed for ventricular unloading in the setting of STEMI care followed immediately by PPCI U-DR Unloading with delayed reperfusion - Impella placed for ventricular unloading in the setting of STEMI care followed by a longer period of unloading before PPCI (in STEMI DTU duration was prespecified as 3 minutes) Primary PCI or PPCI A coronary interventional procedure usually with coronary stenting (PCI) performed in the setting of a STEMI Unloading Reduction of mechanical power expenditure (PVA x HR) 1 of the ventricle to minimize myocardial oxygen consumption (MVO2) and reduce hemodynamic forces that lead to ventricular remodeling and, in MI, to reduce infarct size MACCE Major adverse cardiac and cerebral events (a composite endpoint of death, MI, stroke or repeat revascularization) Infarct Size /Total LV Mass (%) An imaging evaluation usually with CMR to assess the % of the entire heart which has sustained an infarction larger infarct % correlates with greater post MI sequela Infarct Size / Area at Risk (%) An imaging evaluation usually with CMR to assess the % of the portion of the heart that was ischemic or in jeopardy which has sustained an infarction - larger infarct % correlates with greater post MI sequela Myocardial Salvage Index (%) (MSI) A calculated assessment of the amount of heart salvaged calculated as 1- Infarct Size/ Area at risk a greater MSI correlates with greater amount of infarct area that was rescued from infarction by the intervention Microvascular Obstruction (%) Or no-reflow phenomenon is an established complication of coronary reperfusion therapy for acute myocardial infarction; recognized as a poor prognostic indicator and marker of subsequent adverse LV remodeling, evaluation by CMR is particularly useful in STE or STE Sum score of ST segment elevation a measurement made by adding the maximal ST segment elevation in mm on each of the 12 ECG leads to assess the extent of myocardium in jeopardy CMR Cardiac magnetic resonance imaging also Cardiac MR or Cardiac MRI TIMI Flow A scoring system from 3 of the coronary flow rates estimated visually on angiography developed by investigators at Thrombolysis in Myocardial Infarction Study Group. TIMI flow (no perfusion) refers to the absence of any antegrade flow beyond a coronary occlusion. TIMI 1 flow (penetration without perfusion) is faint antegrade coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed. TIMI 2 flow (partial reperfusion) is delayed or sluggish antegrade flow with complete filling of the distal territory. TIMI 3 is normal flow which fills the distal coronary bed completely LVEF Left ventricular ejection fraction the amount of volume of blood ejected from the heart each beat expressed as a percent of the diastolic volume LVEDP Left ventricular end diastolic pressure in mmhg MAP Mean arterial pressure in mmhg CRISP-AMI A study evaluating use of Intra-aortic balloon pump (IABP) placed before reperfusion in Anterior STEMI results failed to show a benefit compared to PPCI alone with a trend toward larger infarcts with IABP published in JAMA. 211;36(12):
2018 TCT Investor Update
1 2018 TCT Investor Update September 2018 LEGAL DISCLAIMERS 2 This presentation contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the
More informationRationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
More informationRationale for Left Ventricular Support During Percutaneous Coronary Intervention
Rationale for Left Ventricular Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Associate Professor, Division of Cardiology Director, Acute Circulatory Support Program
More informationIntroduction to Acute Mechanical Circulatory Support
Introduction to Acute Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive
More informationRay Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California
High Risk PCI Making Possible the Impossible Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California Disclosures Abiomed Research Support Consulting Agreement
More informationTREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4
1 TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA FDA APPROVES IMPELLA FOR HIGH-RISK PCI 2 Impella is the only hemodynamic support device proven safe and effective in elective
More informationAcute Myocardial Infarction Complicated by Cardiogenic Shock
Acute Myocardial Infarction Complicated by Cardiogenic Shock Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional
More informationIntraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
More informationPercutaneous Mechanical Circulatory Support Devices
Percutaneous Mechanical Circulatory Support Devices Daniel Vazquez RN, RCIS Miami Cardiac & Vascular Institute FINANCIAL DISCLOSURES none CASE STUDY CASE STUDY 52 year old gentlemen Complaining of dyspnea
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationLong-Term Management: Preventing Progression. Daniel Burkhoff Cardiovascular Research Foundation and Columbia University
Long-Term Management: Preventing Progression Daniel Burkhoff Cardiovascular Research Foundation and Columbia University Disclosure Unrestricted institutional (CRF) educational grant from Abiomed Left Ventricular
More informationABIOMED TCT INVESTOR UPDATE: 2017
ABIOMED TCT INVESTOR UPDATE: 2017 A GROWING POPULATION OF HIGH RISK AND CARDIOGENIC SHOCK PATENTS LEGAL DISCLAIMERS This presentation contains forward-looking statements, including statements regarding
More informationAssist Devices in STEMI- Intra-aortic Balloon Pump
Assist Devices in STEMI- Intra-aortic Balloon Pump Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center Athens, Greece Cardiogenic shock 5-10% of pts after a heart attack 60000-70000 pts in Europe/year
More informationThe Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities
The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure
More informationMODULE 2 THE CLINICAL ENIGMA: RANDOMIZED TRIALS vs CLINICAL PRACTICE. Nico H. J. Pijls, MD, PhD Catharina Hospital Eindhoven The Netherlands
MODULE 2 THE CLINICAL ENIGMA: RANDOMIZED TRIALS vs CLINICAL PRACTICE Nico H. J. Pijls, MD, PhD Catharina Hospital Eindhoven The Netherlands Disclosure All presenters have a speaker agreement with Maquet
More informationCase - Advanced HF and Shock (INTERMACS 1)
Case - Advanced HF and Shock (INTERMACS 1) Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive Director,
More informationMechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida DISCLOSURE Presenter:
More informationMechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Chief Medical Officer First Coast Cardiovascular Institute, Jacksonville, FL Professor of Medicine, UCF, Orlando, FL None DISCLOSURE Percutaneous
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationCirculatory Support: From IABP to LVAD
Circulatory Support: From IABP to LVAD Howard A Cohen, MD, FACC, FSCAI Director Division of Cardiovascular Intervention Co Director Cardiovascular Interventional ti Laboratories Lenox Hill Heart & Vascular
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationManagement of Acute Shock and Right Ventricular Failure
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering, Cleveland Clinic NONE Disclosures CARDIOGENIC SHOCK
More informationCardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands
Cardiogenic Shock Dr. JPS Henriques Academic Medical Center University of Amsterdam The Netherlands Conflict of interest disclosure Research grant Abbott Vascular Research grant Abiomed Inc. Global Impella
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM Michael Minogue Chairman, President, & CEO January 8, 2018 LEGAL DISCLAIMERS 2 This presentation contains forward-looking statements, including statements regarding development
More informationpresenters 2010 Sameh Sabet Ain Shams University
Guidelines for PCI in late STEMI presenters 2010 Sameh Sabet Assistant Professor of Cardiology Ain Shams University 29% of MI patients have STEMI. NRMI 4 (Fourth National Registry of Myocardial Infarction),
More informationA National Cardiogenic Shock Initiative (CSI):
A National Cardiogenic Shock Initiative (CSI): Insights from the Impella Quality (IQ) Program, cvad Registry and the Detroit CSI Experience William O Neill, MD, FACC Medical Director Structural Heart Disease
More informationAntonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017
Parigi: May 16-19, 2017 Miracor Symposium Speaker: 15 Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy Nothing to disclose PiCSO Impulse System Elective high risk
More informationOutcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella
Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella William O Neill, MD, FACC Medical Director Structural Heart Disease at Henry Ford Hospital, MI AMI Shock Mortality
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationMatching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support
Matching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced
More informationA case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD
A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD NAVAL HOSPITAL OF ATHENS case presentation Female, 81yo Hx: diabetes mellitus, hypertension, chronic anaemia presented
More informationCardiogenic Shock Protocol
Cardiogenic Shock Protocol Impella Devices Best Practices in AMI Cardiogenic Shock Identify 1-3 SBP < 90 mmhg or on inotropes /pressors Cold, clammy, tachycardia Lactate elevated > 2 mmoi /L Stabilize
More informationNo-reflow Phenomenon in Patients with Acute Myocardial Infarction: Its Pathophysiology and Clinical Implications
No-reflow Phenomenon in Patients with Acute Myocardial Infarction: Its Pathophysiology and Clinical Implications * 164 Ito Acta Med. Okayama Vol. 63, No. 4 Normal case Anterior MI Fig. 3 Myocardial contrast
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationSTEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.
STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. PART 1 Systems of care for STEMI. STEMI Management Coronary angiogram +/- stenting. Prehospital thrombolysis
More informationImpella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials
Accepted Manuscript Impella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials Dagmar M. Ouweneel, MSc, Erlend Eriksen, MD, Melchior Seyfarth,
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationFFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators
FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM Michael Minogue Chairman, President, & CEO January 2019 LEGAL DISCLAIMERS 2 This presentation contains forward-looking statements, including statements regarding development
More informationIABP SHOCK II trial:
IABP SHOCK II trial: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic
More informationSTEMI ST Elevation Myocardial Infarction
STEMI ST Elevation Myocardial Infarction Breakout Session One Moderators: Quinn Capers IV, MD and Scott M. Lilly, MD, PhD Cases Presented by: Umair S. Ahmad, MD 1 Outline 1. Multivessel Revascularization
More informationPercutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.
UvA-DARE (Digital Academic Repository) Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. Link to publication Citation for published version
More informationManagement of Cardiogenic shock. Prof. Christian JM Vrints
Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease
More informationCNR, G. Monasterio Foundation, Clinical Physiology Institute Pisa
CNR, G. Monasterio Foundation, Clinical Physiology Institute Pisa Stockholm Aug 29, 2010 Role of MRI in the acute Myocardial Infarction? massimo lombardi Two days after infarct (top row), the T2 hyperintense
More informationGuideline compliance, utilization trends
Guideline compliance, utilization trends and device selection Tilmann Schwab Cardiology / Intensive care Cardiac support IABP LVAD Transluminal l LVAD Cardiac support Emergency cardiac life support (ECLS)
More informationThe Robert TV Kung Interventional Heart Failure Fellowship Program Bringing Hope to the Hopeless at Tufts
The Robert TV Kung Interventional Heart Failure Fellowship Program Bringing Hope to the Hopeless at Tufts Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional
More informationCOURSE OFFERINGS. Committed to Improving Outcomes in Cardiogenic Shock and Protected PCI Through Excellence in Education.
2017 COURSE OFFERINGS Committed to Improving Outcomes in Cardiogenic Shock and Protected PCI Through Excellence in Education. ABOUT THIS COURSE BOOKLET Abiomed offers a full curriculum of educational programs
More informationAnnie Chou Internal Medicine PGY3 University of British Columbia. Rocky Mountain Internal Medicine Conference November 24, 2011
Annie Chou Internal Medicine PGY3 University of British Columbia Rocky Mountain Internal Medicine Conference November 24, 2011 Role of the ECG in STEMI Diagnosis of myocardial infarction Localization of
More informationCath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)
Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO) Michael A. Gibson, MD Assistant Professor of Medicine University of California, Irvine Division of Cardiology
More informationRhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale
A Randomized Clinical Study To Compare The Intra-Aortic Balloon Pump To A Percutaneous Left Atrial-To-Femoral Arterial Bypass Device For Treatment Of Cardiogenic Shock Following Acute Myocardial Infarction.
More informationIMR in acute STEMI and clinical outcomes
IMR in acute STEMI and clinical outcomes Professor Colin Berry Golden Jubilee National Hospital, University of Glasgow. ETP Coronary Physiology 24 April 2015 Disclosures Speaker - Shire Pharmaceuticals,
More informationBuilding a Stroke Portfolio. June 28, 2018
Building a Stroke Portfolio June 28, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: the potential benefits, safety and efficacy
More informationHigh Risk PCI for Heart Failure
High Risk PCI for Heart Failure Ray Matthews MD Professor of Clinical Medicine Chief, Division of Cardiovascular Medicine University of Southern California Los Angeles, California Disclosures Abiomed Research
More informationRole of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이
Role of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이 Outline Evaluation of Chest pain Evaluation of MI complications Prediction of Outcomes Evaluation of Chest pain Evaluation
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 OSPEDALE Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More informationCardiogenic Shock and Initiatives to Reduce Mortality
Cardiogenic Shock and Initiatives to Reduce Mortality Tanveer Rab, MD, FACC William O Neill, MD, FACC Perwaiz Meraj, MD, FACC Alex Truesdell, MD, FACC The Golden Hours? 50% dead within 10 hours Overall
More informationHow to do Primary Angioplasty. - Patients with Cardiogenic Shock
How to do Primary Angioplasty - Patients with Cardiogenic Shock Advanced Cardiovascular Intervention 2011 Dan Blackman Leeds General Infirmary MY CONFLICTS OF INTEREST ARE: Research Grants Medicines Company
More informationThe Case for Multivessel Revascularization in Shock
The Case for Multivessel Revascularization in Shock Emmanouil S. Brilakis, MD, PhD Minneapolis Heart Institute 9.37 9.49 am Disclosures Consulting/speaker honoraria: Abbott Vascular, American Heart Association
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationΦαινόμενο No-Reflow. Απεικόνιση με CMR, κλινική συσχέτιση και προγνωστική σημασία
Φαινόμενο No-Reflow. Απεικόνιση με CMR, κλινική συσχέτιση και προγνωστική σημασία Θεόδωρος. Καραμήτσος MD PhD Honorary Consultant in Cardiology University of Oxford Centre for Clinical Magnetic Resonance
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationCLINICAL DOSSIER Protected PCI
CLINICAL DOSSIER Protected PCI with the Impella Heart Pump Executive Summary Protected PCI with the Impella On March 23, 2015, the Impella 2.5 received PMA approval from the U.S. FDA* and on December
More informationWhen Aspiration Thrombectomy Does Not Work? A A R O N W O N G N A T I O N A L H E A R T C E N T R E S I N G A P O R E
When Aspiration Thrombectomy Does Not Work? A A R O N W O N G N A T I O N A L H E A R T C E N T R E S I N G A P O R E Thrombus in STEMI Over 70% of STEMI patients has angiographic evidence of thrombus
More informationPiCSO to Improve Myocardial Salvage and Reduce Infarct Size in STEMI: Emerging Data
PiCSO to Improve Myocardial Salvage and Reduce Infarct Size in STEMI: Emerging Data Azfar G. Zaman, MD Freeman Hospital, Newcastle upon Tyne, UK Disclosure Statement of Financial Interest Within the past
More informationManagement of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
More informationAcute Mechanical Circulatory Support Right Ventricular Support Devices
Acute Mechanical Circulatory Support Right Ventricular Support Devices Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure
More informationThe majority of patients with cardiomyopathy
Selection of Hemodynamic Support: An Approach for Coronary Interventions in Shock and High-Risk PCI The role of hemodynamic support devices in emergent cardiogenic shock and elective high-risk percutaneous
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationImpella Ins & Outs. CarVasz November :45 12:15
Impella Ins & Outs CarVasz November 21 2014 10:45 12:15 Nicolas M. Van Mieghem, MD, PhD, FESC Clinical Director of Interventional Cardiology Thoraxcenter, Erasmus MC Rotterdam Background IABP is widely
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationLivaNova Investor Day
LivaNova Investor Day TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) Paul Buckman General Manager, TMVR September 14, 2017 Safe Harbor Statement Certain statements in this presentation, other than purely
More informationExtra Corporeal Life Support for Acute Heart failure
Extra Corporeal Life Support for Acute Heart failure Benjamin Medalion, MD Director Heart and Lung Transplantation Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus, Israel Mechanical
More informationA Future for the IABP in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany
A Future for the in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany Disclosures Funding: German Research Foundation German Heart Research
More informationPharmaco-Invasive Approach for STEMI
Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),
More informationWho is the high risk patient?
Who is the high risk patient? High risk of periprocedural death or other major complications (hemodynamic compromise, MI, stroke, dialysis) Contributors of Risk Lesion/Procedure Governed by 1. Patient
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationPathophysiology of ischemia-reperfusion injury (and how to protect against it )
Pathophysiology of ischemia-reperfusion injury (and how to protect against it ) Dr Derek J Hausenloy Reader in Cardiovascular Medicine BHF Senior Clinical Research Fellow Honorary Consultant Cardiologist
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary Conflicts of interest Advisory Boards Cordis Boston Scientific
More informationMCS for Acute Heart Failure Eric Adler MD Associate Professor of Medicine Medical Director Cardiac Transplant
MCS for Acute Heart Failure 2016 Eric Adler MD Associate Professor of Medicine Medical Director Cardiac Transplant Why do we decompensate? Which Heart Failure Patients Should Get Palliative Care and Who
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial
More informationManagement of new-onset AF: Initial rate control treatment
Geneva Acute Crdiovascular Care Congress 2014 - October 18-20, 2014 Management of new-onset AF: Initial rate control treatment Antonio Raviele, MD, FESC, FHRS ALFA Alliance to Fight Atrial fibrillation,
More informationTed Feldman, M.D., MSCAI FACC FESC
Support Technologies and High Risk Intervention Patient Selection: When Not to Use Them Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas December 7-10 th, 2014 Ted
More informationInfluence of Location and Size of Myocardial Infarction on Post-infarction Remodelling
Influence of Location and Size of Myocardial Infarction on Post-infarction Remodelling Masci PG, MD ; Ganame J, MD ; Francone M, MD, PhD # ; Desmet W, MD ; Iacucci I, MD # ; Barison A, MD ; Carbone I,
More informationThrombus Aspiration before PCI: Routine Mandatory. Professor Clinical Cardiology Academic Medical Center University of Amsterdam
Seoul, 27 April TCT AP 2010 Thrombus Aspiration before PCI: Routine Mandatory Robbert J de Winter MD PhD FESC Professor Clinical Cardiology Academic Medical Center University of Amsterdam AMC Amsterdam
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationMechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017
Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017 Pascal Vranckx MD, PhD. Medical director Cardiac Critical Care Services Hartcentrum Hasselt Belgium Disclosure
More informationRational use of imaging for viability evaluation
EUROECHO and other imaging modalities 2011 Rational use of imaging for viability evaluation Luc A. Pierard, MD, PhD, FESC, FACC Professor of Medicine Head, Department of Cardiology, CHU Liège, Belgium
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM Michael Minogue Chairman, President, & CEO LEGAL DISCLAIMERS 2 This presentation contains forward-looking statements, including statements regarding development of Abiomed's
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationThe Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize
The Role of Mechanical Circulatory Support in Cardiogenic Shock: Presented by Nancy Scroggins ACNP, CNS-CC CV Surgery ACNP Bayshore Medical Center The Role of Mechanical Circulatory Support in Cardiogenic
More informationThe number of patients in the United States with
Treating the Growing Population of Patients With High-Risk, Complex Coronary Artery Disease: Protected PCI With Impella BY SETH BILAZARIAN, MD, FACC, FSCAI The number of patients in the United States with
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More information